iCAD (NASDAQ:ICAD) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

iCAD, Inc. (NASDAQ:ICAD) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.57 and traded as high as $1.78. iCAD shares last traded at $1.78, with a volume of 282,089 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

iCAD Stock Up 5.6 %

The stock has a fifty day moving average of $1.81 and a 200-day moving average of $1.57. The stock has a market capitalization of $47.24 million, a price-to-earnings ratio of -13.69 and a beta of 1.43.

Institutional Trading of iCAD

A hedge fund recently raised its stake in iCAD stock. Perritt Capital Management Inc grew its position in iCAD, Inc. (NASDAQ:ICAD) by 14.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,900 shares of the technology company’s stock after acquiring an additional 19,917 shares during the quarter. Perritt Capital Management Inc owned about 0.60% of iCAD worth $208,000 at the end of the most recent reporting period. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.